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TNF/cachectin has diverse physiological functions and is produced by a wide va-
riety ofcell types (reviewed in reference 1). Recently, evidence has accumulated that
TNF may play regulatory roles in T and B lymphocyte activation, proliferation,
anddifferentiation (2, 3) . ActivatedT cellshave been shown to produce aconsider-
able amount of TNF (4-6) . However, the capacity of B cells to produceTNF has
not been documented fully. Bersani, et al . (7) could detect only lymphotoxin (LT)'
but notTNF in the supernatants of tonsillar B cells activatedby Staphylococcus aureus
Cowan I strain (SAC) . In the present study, we found that a number ofB leukemia
andEBVtransformed B cellsexpressed TNF at both themRNA and protein levels .
Tonsillar B cells could also be induced by mitogens to synthesizeTNFmRNA and
to secreteTNF . TNF production by these B cells correlated with their proliferative
responsiveness to the mitogenic stimuli, and it may play important roles in B cell
activation, growth, and development .
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Materials and Methods
Reagents.
￿
Goat anti-g IgG was affinity purified after absorption with mouse, rabbit, and
fetal calf sera, and human IgG and IgA . AntiTNF mAbs C16, F12, and E43 have been de-
scribed (5) . The concentrations of stimulants used were as follows : anti-g IgG, 25 gg/ml ;
SAC (Calbiochem-Behring Corp ., La Jolla, CA), 0.01% ; B cell growth factor (BCGF; Cel-
lular Products, Buffalo, NY), 5% ; PMA (Sigma Chemical Co., St . Louis, MO), 10 ng/ml;
LPS (from S . typhosa ; SigmaChemical Co.), 5 pg/ml ; IFN-y (Cellular Products), 100 U/ml ;
cyclosporin A (CsA; Sandoz, East Hanover, NJ), 5 pg/ml; anti-CD3, 1 gg/ml ; and A23187
(Calbiochem-Behring Corp .), 0.1 gM .
Cells.
￿
Cells were maintained in RPMI 1640 with 10% FCS as described (5). TheB cell
lines used were from Dr.JunMinowada (Fujisaki Cell Center, HayashibaraBiochem . Labs,
Inc., Fujisaki, Okayama, Japan), the American Type Culture Collection (Bethesda, MD),
or derived in our own laboratory (8). The Ig expressions of cell lines derived from Burkitt's
lymphoma patients are as follows : Daudi, p'8* K* ; Raji, p' ; and Ramos, p' X' . The leukemia
cell line Ig expressions are SeD, 4'8'K' ; Nalm-6, cytoplasmic p' ; and Nalm-12, cytoplasmic
g' . The EBVtransformed cell line Ig expressions arejosh 7, Ig- (9); 32al, a' X' ; 8866P,
Y' ic' ; RPMI 1788, p' S'X' . Other EBVtransformed B cell lines were derived from T
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cell-depleted human bone marrow cells as described (9). These cells express: WIH8, y' k` ;
WIH10, a'x' ; WIH14, a'x' ; WIH20, la'x' ; WIH67, y' X' ; and KAW15, y' X' .
Tonsillar B cells were isolated by Ficoll-Hypaque gradient centrifugation, followed by T
cell depletion by E-rosetting twice (5). Monocytes/macrophages were depleted from B cells
by counterflow centrifugal elutriation as described (5). The final B cell preparations con-
tained <0.1% macrophages and >95% Ig' and >98% CD20' cells, as determined by fluores-
cence measurements on a flow cytometer(Cytofluorograf IIs, model 50H; Ortho Diagnostic
Systems, Inc., Westwood, MA). Tonsillar T cells were isolated by E-rosetting twice. These
cells were':>95% CD2' and CD3' .
Northern Blot Analyses.
￿
Northern blot analyses using RNA prepared from guanidinium
thiocyanate ultracentrifugationhave been described(5). A 3.4-Kb human genomicTNFPst-
I fragment (5) and a human TNFcDNA clone from Drs. B. Beutler(Howard Hughes Med-
ical Institute, Dallas, TX) and D. Caput (Chiron Research Laboratories, Emeryville, CA)
were used in Northern blots. The Cx (Sac I fragment; reference 10) andCX (Barn HI-HindIII
fragment; reference 11) probes were subcloned from genomic clones generously provided by
Dr. Phillip Leder (Harvard Medical School, Boston, MA). Other cDNA probes have been
described (5). In some experiments, equal amounts of exogenous globin mRNA (Bethesda
Research Laboratories, Bethesda, MD)were added to each ofthesamplesbefore guanidinium
thiocyanate ultracentrifugation as an internal standard. The recoveries of RNA in the in-
dividual samples were compared by probingthe blotswith an a-globin probe (pjW101, ATCC)
and were found to be essentially identical.
TNFRIA.
￿
TNFin culture supernatants wasquantitated by a sandwich assay usingE-43
antiTNF mAb as the immobilized primary antibody and '21I-labeled F12 antiTNF mAb
(sp act ti5 x 107 cpm/wg protein) as the secondary tracer antibody. rTNF (Amgen, Thou-
sand Oaks, CA.) was used as standards. The assay was linear up to 500 pg rTNF and the
detection limit was -2 .5 pg. Nonspecific binding in samplescontaining goat anti-R antibody
was blocked by 5% mouse serum during incubation of the plates with the secondary iodi-
nated antibody.
Results
B Cell Lines Express TNF mRNA.
￿
A group of well established B cell lines were
analyzed for TNF mRNA expression (Fig. 1 A). Three patterns were apparent. The
Burkitt lines Daudi, Raji, and Ramos, the pre-B leukemia line Nalm 12, and the
EBVtransformed precursor B lymphoblastoid line, Josh 7, did not constitutively
express TNF mRNA. PMA induced TNF mRNA in these lines readily. Low levels
of TNF mRNA were detected in theunstimulated Blymphoblastoid linesSeD, 8866P,
32al, and RPMI 1788. Higher levels ofTNF mRNA were induced with PMA. The
pre-13 leukemia line Nalm 6 did not produce TNF mRNA even when stimulated
with PMA. An actin probe was included as a control. x and X L chain probes
confirmed that Lchain mRNA wasreadilydetectable. Lowlevels ofLchainmRNA
were shown in four pre-B cell lines. They may represent aberrant mRNA because
no L chain proteins were detected. Newlyestablished EBVtransformed B cell lines
from bone marrow expressed TNF mRNA constitutively, and PMA induced slight
to moderate increases in TNF mRNA accumulation (Fig. 1 B).
Activated TonsillarB CellsExpress TNFmRNA.
￿
Highly purified tonsillar B cell popu-
lations with >98% CD20' cells were used for analysis. Unstimulated tonsillar B
cells in control medium for 24 h did not make TNF mRNA, as shown by Northern
blot analysis. B cell mitogens such as PMA, anti-p antibody, BCGF, and SAC were
used in various combinations. Our goat anti-p antibody was weakly mitogenic. It
was synergistic with either BCGF or PMA to induce B cell proliferation. The anti-u
antibody did not induce TNF mRNA (Fig. 2 A, lane 2), nordid BCGF at 5% (dataSUNG ET AL .
￿
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Fir,UEE 2 .
￿
TNFmRNA expression in tonsillar B cells stimulated by anti-p (A) and SAC (B),
and inhibition of these stimulations by CsA (C). Purified tonsillar B cells were resuspended at
10 6/ml and treated for 24 h with the drugs indicated. The total RNA was isolated by ultracen-
trifugation and analyzed as in Fig . 1 .One representative experiment offour similar experiments
for A and B, and one of two experiments for C, are shown . (A) Tonsillar B cells (1 .7 x 10 1
cells/sample) were treated with control medium (lane 1), anti-u (lane 2), PMA (lane 3), PMA
plus anti-u (lane 4), PMA plusBCGF (lane 5), anti-p plus BCGF (lane 6), andPMAplus anti-tt
plus BCGF (lane 7) . (B) Tonsillar B cells (2.8 x 10 cells/sample) were treated with control
medium (lane 1), SAC (lane 2), PMA(lane 3),PMAplus SAC (lane 4), SAC plusBCGF (lane
5), PMA plus SAC plus BCGF (lane 6), SAC plus anti-ji (lane 7), and SAC plus anti-u plus
BCGF (lane 8). (C) TonsillarB cells (lanes 1-11) and T cells (lanes 12-16) at 2.1 x 10 7 cells/sample
were treated with the following reagents: lanes 1 and12, controlmedium ; lanes 2and 13, PMA;
lane 3, SAC; lanes 4 and 14, PMA plus CsA; lane 5, SAC plus CsA; lane 6, PMA plus SAC ;
lane 7, PMAplusSAC plusCsA ; lane 8, PMA plus anti-W ; lane 9, PMA plus anti-u plus CsA ;
lane 10, SAC plus BCGF; lane 11, SAC plus BCGF plus CsA; lane 15, PMA plus anti-CD3 ;
and lane 16, PMA plus anti-CD3 plus CsA . In the lower panel showing actin hybridizations,
lanes 1-11 were exposed twice as long as lanes 12-16.
not shown) . PMA (Fig. 2 A, lane 3 ; B, lane 3 ; C, lane 2) and SAC (Fig . 2 B, lane
2; C, lane 3) stimulated B cells to accumulate low levels of TNF MRNA . Anti-p
(Fig . 2 A, lane 4 ; C, lane 8) and SAC (Fig . 2 B, lane 4 ; C, lane 6) were strongly
synergistic with PMA and induced 5-10-fold higher accumulation of TNF mRNA
thanPMA alone . BCGF increasedPMA stimulation about two-fold (Fig . 2 A, lane
5), and SAC stimulation two- to threefold (Fig. 2 B, lane 5) . BCGF also slightlySUNG ET AL .
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increased (more than twofold) stimulations by PMA plus SAC (Fig . 2 B, lane 6)
and PMA plus anti-g (Fig. 2 A, lane 7), but did not increase anti-11 stimulation
(Fig. 2 A, lane 6). The effects of anti-fit and SAC on TNF mRNA accumulation
in tonsillarB cells were not additive (Fig . 2 B) . In fact, anti-g abolished the stimula-
tion by SAC (lane 7), andBCGF plus SAC induced no detectable TNF mRNA in
the presence of anti-p (lane 8) . TotalmRNA in these B cells, shown as actinmRNA
accumulation, increased with B cell proliferation but did not strictly correlate with
TNF accumulation . For example, BCGF plus SAC (Fig 2 B, lane 5) caused a rela-
tively higher increase in actin than TNF mRNA accumulation .
Time Course ofTNFmRNA Accumulation in B Cells .
￿
The kinetics ofTNF mRNA
accumulation in PMA plus SAC-treated tonsillar B cells was examined (Fig . 3 A) .
Control B cells had no detectable TNF mRNA . mRNA was detectable at 4 h (not
shown) . At 24 h, substantial amounts ofTNF message were accumulating . Max-
imal accumulation was observed at 32 h . This peak accumulation was maintained
up to 48 h, and the message level decreased slowly thereafter until 120 h when a
level comparable with that at 8 h was detected (not shown) . No IL-2 mRNA could
be detected in these stimulated B cells .
To rule out the possibility that theTNF mRNA detected in these B cell prepara-
tions was due to contaminatingTlymphocytes, the kinetics ofTNFmRNA accumu-
lation in T cells stimulated with PMA plus SAC, and PMA plus anti-CD3 were
examined . In contrast to B cells, T cells barely responded to PMA plus SAC (Fig.
3 A) . The small increase in TNF mRNA detected was probably due to the effects
ofPMA on T cells . However, when stimulated with PMA plus anti-CD3, tonsillar
Tcells exhibited an increase in TNFmRNA with similar kinetics as B cells, showing
peak accumulation at 32-48 h, and agradual decrease inTNFmRNA over thenext
72 h. The peak TNFmRNA accumulation was about twofold over that of B cells
on a per cell basis . IL-2mRNA accumulation showed similar kinetics toTNFmRNA
accumulation. Thekinetics ofTNFmRNA accumulation in B cells stimulated with
PMA plus anti-u was also examined . Maximal accumulation also occurred at-48 h
(not shown) .
The B cell line RPMI 1788, which produced high levels of TNF mRNA when
stimulated with PMA, was used to study the time course ofTNFmRNA accumula-
tion in B cell lines . PMA-stimulated TNF mRNA accumulation was maximal at
1 h and decreased rapidly with time (Fig . 3 B) . By 6-8 h, a very low message ac-
cumulation above control level wasobserved . Cells treated with A23187 alone showed
no increase in TNFmRNA (not shown) . A23187 plus PMA induced two- to three-
fold increase in TNFmRNA accumulation over that attained withPMA stimula-
tion alone. The maximal accumulation with the combination treatment occurred
at between 1 and 2 h . Theelevated TNFmRNA level was also more sustained than
that in PMA-treated cells .
Production of TNF by B lymphocytes.
￿
The production ofTNF by B lymphocytes
was examined by Western blots and a quantitative RIA . The production of TNF
by the three cell lines, SeD, RPMI 1788, andWIH8, stimulated with PMA, was
examined by Western blots (Fig . 4) . The 17-kDTNF protein band absent in blots
probed with a controlmAb could be detected in the supernatants of all three cell
lines. The band at 25 kD in SeD supernatants (Fig. 4, lanes X and 2) was due to
the crossreactivity of IgLchain with the secondary goat anti-mouse antibody, since1544
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FIGURE 3 .
￿
Time course ofTNFmRNA expression in tonsillarB andT cells (A) andtheB cell
lines RPMI 1788 (B) . (A) Tonsillar B cells (lanes 1-5) andT cells (lanes 6-15) at 106 cells/ml
(20 ml per sample) were treated for the indicated time period withPMA plus SAC (lanes 1-10)
or PMAplus anti-CD3 (lanes 11-15), and their totalRNAwas analyzed by Northern blots . The
same blot wasprobed successively with TNF, IL-2, and actin probes. Oneofthree similar experi-
ments is shown . (B) RPMI 1788 cells were suspended at 2.5 x 10 5/ml and treated with PMA
(lanes 2-10) or PMA plus A23187 (lanes 11-19) for the indicated time period . Total RNA (20
jig/lane) was analyzed by Northern blots . The figure shows one of two similar experiments.
the presence ofhuman Ig fraction during incubation with the secondary antibody
blocked this staining (Fig . 4, lane 3) . Tonsillar B cells stimulated with PMA plus
SAC also produced the 17-kD TNF detected by Western blotting (Fig. 4 B) . The
quantity was less than that produced by thethree B cell lines examined, as discussed
later.
Aquantitative RIAwasused to measure the amount ofTNFproduced by B cells .
The B cell lines RPMI 1788, and the EBVtransformed bone marrow-derived BSUNG ET AL .
￿
1545
FIGURE 4 .
￿
Western blot of supernatant proteins isolated from B cell lines and tonsillar B cells .
(A) Supernatants from SeD (lanes 1-3), RPMI 1788 (lanes 4-6), and WIH8 (lanes 7-9) stimu-
lated with PMA in serum-free RPMI 1640 medium for 24 h were concentrated and analyzed
by Western blots (5) . Lanes 1, 4, and 7were treated with a control antibody (HDP-1) and lanes
2, 3, 5, 6, 8, and 9were treated with C16 antiTNFmAb . In lanes 3, 6, and 9, crossreactivities
with the secondary antibody were blocked with humangamma globulin fraction (17o). (B) Ton-
sillar B cells (108 total) were resuspended at 2 x 106/ml and prestimulated with PMA plus SAC
in RPMI 1640 with 107o FCS for 24 h . The cells were washed and resuspended in serum-free
medium containing stimulants. Serum-free supernatants collected over a 3-d period with daily
medium changes were concentrated and analyzed by Western blots . Lanes 1 and 2 contained
protein from WIH8 supernatants and lanes 3and 4 were tonsillar B cell supernatant proteins .
Lanes 1 and3 were probed with control mAb HDP-1 while lanes 2and 4were probed with C16
antiTNF mAb .
cell linesWIH8 and KAW15 at 106 cells/ml, produced 5-7 ng/mlTNF in 24 h when
cultured in medium containing 10 ng/mlPMA(Table 1) . The combination ofPMA
and A23187 did not further increase the amount ofTNF produced within this 24-h
period, although the TNF mRNA level in these cells was higher (Fig . 3 B) . The
amount ofTNF produced by these cell lines is comparable with that produced by
a myeloid cell line, ML-1 . Molt-4, aT cell line that can be stimulated to synthesize
LT, but not TNFmRNA, did not produce any detectableTNF . Interestingly, little
TNF could be detected in the supernatants ofthe unstimulated B cell lines, though
they accumulated moderate levels of TNF mRNA (Fig . 1) .
The production ofTNF by tonsillar B cells stimulated with various mitogens was
examined (Table II). Control B cells and B cells stimulated with anti-w, or anti-11
plusSAC, did not produceanydetectable amount ofTHE PMA orSAC alonestimu-
lated B cells to produce 100-300 pg/ml ofTHE PMA plus anti-p and PMA plus
SAC, which stimulated the accumulation of high levels of TNF mRNA in B cells,
induced the synthesis ofTNF, and 400-1,500pg/mlTNFwas found in the medium .
The combination of the three stimulants, PMA, anti-fit, and SAC, caused a further
twofold increase in medium TNF to a maximal concentration of 2,700 pg/ml . The
maximal TNF concentration in medium occurred on the second day of culture .1546
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Supernatants
Tonsillar B cells
Peripheral blood monocytes
TABLE I
TNF Concentration in Supernatants ofB Cell Lines
Cells were resuspended in medium containing 10% FCS at 106/ml and treated
as indicated for 24 h. TNF concentrations in supernatants were measured by
RIA and expressed as mean t SD .
The production ofTNF by B cells wascompared with that by T cells and macro-
phages . Tcells stimulated with PMA plus anti-CD3 orPMAplus 9.3 (anmAb against
CD28), accumulated 5-10-fold moreTNF in the medium . These values are com-
parablewith those published by Cuturi et al . (4). Peripheral blood monocytes stimu-
TABLE II
Concentrations of TNF in the Supernatants of Tonsillar B Cells andT Cells, and
Peripheral Blood Monocytes
TNF concentration'
pg/ml
B and T cells were purified as described in Materials and Methods. Monocytes were purified by percoll
gradients (5) . Cells were suspended at 106/ml and treated with the indicated reagents . The results represent
one of three similar experiments.
' Cell supernatants (100 pl) in duplicates were assayed for TNF by an RIA as described in Materials and
Methods. Values represent mean t SD .
t PMA was used at I ng/ml .
C
Anti-p
Anti-V + SAC
PMA
<25
<25
<25
14016
<25
<25
<25
26018
<25
<25
<25
1601 1
SAC 270 t 8 280 t 10 170 t 18
PMA + anti-p 310 1 1 1,550 1 17 650 1 9
PMA + SAC 1,050 t 11 1,450 t 53 400 t 14
PMA + anti-p + SAC 840 t 10 2,700 ± 118 1,440 t 45
Tonsillar T cells
C <25 <25 <25
Anti-CD3 <25 <25 <25
PMA ND ND 221 ± 50
PMA + anti-CD3 7,660 t 260 14,090 t 192 22,840 t 526
C 130 t 3 ND ND
LPS 480 t 51 ND ND
IFN-y 250 t 5 ND ND
LPS + IFN-T 3,140 t 100 ND ND
PMA$ 11,770 t 310 ND ND
Supernatants No stimulus
TNF concentration
PMA
pg/ml
PMA + A23187
RPMI 1788 38 t 3 4,730 ± 110 3,920 ± 300
WIH8 470 t 10 7,150 t 70 7,540 ± 30
KAW 15 120 ± 3 5,160 t 90 5,380 t 30
ML-1 <25 6,630 t 450 5,530 t 180
Molt-4 <25 <25 <25SUNG ET AL.
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lated with IFN-y produced little TNF. LPS, or IFN-y plus LPS, stimulated mono-
cytes to produce 0.5-3 ng/ml TNF. PMA, though toxic to monocytes, caused the
releaseofti12 ng/ml THE Monocytes without added stimuli also secreted some THE
Inhibition of B Cell TNF Expression by CsA.
￿
Since CsA inhibited the expression
of IL-2 and IFN-y mRNA in T lymphocytes and B cell proliferation (12-14), the
effects of CsA on TNF mRNA expression were examined. CsA did not affect the
TNF mRNA level in cells stimulated with PMA alone in both B and T cells but
abolished the expression of TNF mRNA in cells stimulated with SAC or BCGF
plus SAC (Fig. 2 C, compare lane 3 with 5 and lane 10 with 11). The potentiation
effects ofPMA stimulation ofTNF mRNA accumulation by anti-1, or SAC in ton-
sillar B cells and anti-CD3 in tonsillar T cells were markedly depressed by 5 jig/ml
CsA (Fig. 2 C, compare lanes 6, 8, and 15 with lanes 7, 9, and 16, respectively).
Discussion
In this study, TNF production by human B cells at both the mRNA and protein
levels were documented. A largepanel ofB celllinesat differingstages ofdifferentia-
tion was shown to make TNF either constitutively or with the addition of PMA.
The report ofSteffen et al. (6) similarly showed that RPMI 1788 made TNF mRNA.
Nalm-6, a pre-B leukemia cell line, was the only line found not to make TNF even
when stimulated with PMA. Tonsillar B cellsextensively depleted ofmonocytes and
T cells were shown to synthesize TNF in response to B cell mitogens. The purity
ofB cell populations and their responsiveness to B cell mitogens in this system made
it unlikely that TNF production was due to very minorcontaminating cells. Thus,
TNF production by activated B cells is demonstrated.
Recently, TNFhas been shownto enhance theproliferation ofSAC-activatedton-
sillar B cells (2). Our findingthat activated B cells produce TNF furtherimplicates
the importance of this factor in B cell responses. The decrease in TNF concentra-
tions in supernatants ofstimulated tonsillar B cells on day 3 may indicatethat TNF
produced by these B cells was used. Limited attempts to block the proliferative re-
sponses ofB cells to PMA plus anti-p antibody or PMA plus SAC with antiTNF
mAb were not successful. TNFhasbeen shown to enhance the proliferationinduced
by allogeneic cells, and polyclonal antiTNF antibody block the MLR (3). Thus,
it remains possible with different antiTNF antibodiesand morephysiological stimuli
to demonstrate that TNF plays some role in B cell proliferation.
LT is closely related to TNF in structure and function. It has been shown to be
important in B cell proliferation (15). We have also shown that IT is produced by
activated B cells(Sung, S., L. Jung,J. Walters, E.Jeffes, III, G. Granger, and S. Fu,
unpublished results). In addition to TNF and IT, activated B cells are capable of
secreting IL-1 (16, 17), IFN-a (18), and BSF2/IL-6 (19). Thus, it appears that B
cells are an important cell type for cytokine production.
The TNF concentrations measured in the supernatants ofB cellsreflect thediffer-
ence between the rates of synthesis and utilization ofTNF by the B cells. Though
the levels of TNF mRNA in B cells and T cells and their rates of TNF secretion
are not directly comparablebecauseoftherequirement ofdifferentstimulifordifferent
cell types, these values do provide an estimate ofthe potential of each cell type to
synthesize TNFunder immunologicallyresponsive conditions in vivo. It seems that
T lymphocytes have a much higher potential to synthesize TNF, and along with1548
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macrophages, may indeed be the major cell types responsible forTNF production
in general . However, under situations in which B cell-specific stimuli are present,
or in areas of high B cell concentration, TNF production by B cells may be impor-
tant . Of revelance to the latter situation is the finding that TNF occurs in a mem-
brane bound form on macrophages (20, 21) . Whether this form is on B cell mem-
branes and actson adjacent cells via cell-cell contact is currentlyunderinvestigation .
The kinetics of TNF mRNA accumulation in activated tonsillar B and T cells
are similar, peakingat32-48 h(Fig. 3 A) . Thetime course for IL-2mRNA accumu-
lation in tonsillarT cells and for ITmRNA accumulation in both tonsillar B and
T cells is similar to that ofTNF With a different mitogen, namely PHA, peak IL-2
mRNA accumulation has been reported to be at 24 h for tonsillar T cells (22) . In
human peripheral bloodTcells,PMA plus anti-CD3 caused maximalTNFmRNA
accumulation at ti4h (5), andPMA plus PHA-stimulatedTcellsaccumulated IFN-y
and IL-2 mRNA at -12 h (13) . PHA-primed T lymphoblasts expressed IFN-'Y and
IL-2 mRNA maximally 3 h after restimulation (13) . These kinetics of cytokine ac-
cumulation in peripheral blood T cells are quite different from that in tonsillar B
and T cells . The kinetics ofTNF mRNA accumulation is also different in B and
T cell lines . The B cell line RPMI 1788 (Fig . 3 B) and the T cell lines CEM and
SKW3 (5)responded to stimuli muchmore quicklyand showed peak TNF accumu-
lation at 1-2 h. The response of these cell lines to PMA is more pronounced than
either tonsillar or peripheralT and B cells . Similarly, theT cell lineJurkat showed
peak IL-2 and IFN-y accumulation 4-6 and 4-8 h afterPHA plus PMA stimula-
tion, respectively (23) . Thedifferent kinetics in cell lines maybe dueto the fact that
transformation makes cells respond faster to stimuli in expressing theirlymphokine
genes . Thus, the kinetics ofcytokine mRNA expression is related to cellular origin,
stimuli used, and the state of activation of the cells .
The accumulation of TNF mRNA in a number of B cell lines with different Ig
phenotypes was examined in an attempt to correlateTNF expression with different
stages ofB cell differentiation . Three interesting observations were made in this set
ofexperiments . First, the pre-B cell lines, Josh-7, Nalm-6, and Nalm-12, made little
orno detectable TNFmRNA evenwhen stimulated withPMA. These resultswould
lend support to the hypothesis that TNF expression in B cells is developmentally
regulated . Second, a number of recently established EBVtransformed bone
marrow-derived B cell lines accumulated higher levels ofTNFmRNA even when
they were not stimulated . This is in agreement with reports showing that EBV acti-
vates B cell to express their cytokine genes (17, 18, 24) . Third, the TNF levels in
certain EBVtransformed cell line supernatants did not correlate with the cellular
TNFmRNA level (Fig . 1 Band Table I) . This maybe dueto the same translational
control of TNF production that is operational in mouse macrophages (25) .
CsA selectively inhibits the responses of cells to agents that raise the level of
intracellular-free Cat+ (12) . B cell proliferation in response to anti-g, SAC, orBCGF
was inhibited by CsA (14) . Our results showed that the responses ofB lymphocytes
to CsA in cytokine production were similar to that of T cells . CsA inhibited the
direct effect of SAC and the synergistic effects of anti-p or SAC with PMA to in-
crease TNFmRNA expression in much the same way as the inhibition ofanti-CD3
responses in T cells, but did not affect the stimulation of tonsillar B and T cells by
PMA alone (Fig . 2 C). These results support the notions that stimulation by anti-uSUNG ET AL.
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or SAC in B cells is analogous to stimulation by anti-CD3 in T cells and that CsA
has less effects on cellular events related to PKC activation.
Summary
The production ofTNF/cachectin by human B cell lines and tonsillar B cells was
examined. Ofthe 15 B cell lines examined, 9 cell lines synthesize TNF mRNA con-
stitutively. PMA stimulated most cell lines to accumulate increased amounts ofTNF.
SeD, 8866P, 32a1, RPMI 1788, and four bone marrow-derived EBVtransformed
cell lines accumulated high levels of TNF mRNA when stimulated by PMA. TNF
production by these cell lines was examined. RPMI 1788 and WIH8 produced little
TNF constitutively, but synthesized 5-7 ng/ml TNF when stimulated by PMA. A
pre-B cell line, Nalm-6, did not synthesize any detectable amount of TNF mRNA,
even with PMA stimulation. Tonsillar B cells could also be stimulated to produce
TNF PMA or Staphylococcus aureus Cowan I strain (SAC) alone stimulated some TNF
mRNA accumulation, whereas B cell growth factor (BCGF) or anti-p did not. This
accumulation was synergistically elevated by the combinations of PMA and SAC,
or PMA and anti-p . BCGFincreased PMA-, SAC-, PMA plus SAC-, or PMA plus
anti-p-induced TNF mRNA accumulations about twofold. The accumulation of
TNF mRNA in tonsillar B cells stimulated by PMA plus SAC was between 32 and
48 h, the same peak interval as the accumulation of TNF and IL-2 mRNA in ton-
sillar T cells. This is in contrast to PMA or PMA plus A23187-stimulated RPMI
1788 cells in which TNF mRNA accumulation was maximal at 1-2 h. TNF activi-
ties found in tonsillar B cell supernatants correlated with the TNF mRNA levels
in the cells. However, more TNF activity was found on the second-day than the third-
day supernatants, indicatingactive TNF uptake by the B cells. Cyclosporin A (CsA)
inhibited SAC and anti-g responses in B cells in much the same way as the anti-
CD3 responses in T cells. SAC-, PMA plus SAC-, and PMA plus anti-p-stimulated,
but not PMA-stimulated, increases in TNF mRNA accumulations in tonsillar B
cells were inhibited by CsA. TNF production seems to increase in parallel with B
cell proliferation, but the relationship of these two functions needs to be further ex-
amined.
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